Sign In
Buy GRFS
$7.18
-0.100 (-1.37%)
At Close: Jun 23, 2026
GigaGen Doses First Patient in Phase 1 Trial of Anti-CTLA-4 Oncology Drug Candidate GIGA-564 in Advanced Solid Tumors
08:00am, Monday, 20'th May 2024
GIGA-564 is a differentiated anti-CTLA-4 antibody with potential to enhance anti-tumor activity and mitigate immune-related toxicities associated with CTLA-4 blockade
LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Gr
LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Gr
LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Gr
LOS ANGELES, CA / ACCESSWIRE / May 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Gr
Grifols swings to profit, says debt reduction on track
02:19pm, Tuesday, 14'th May 2024
Spanish drugmaker Grifols swung to a first-quarter net profit of 21 million euros ($23 million) from a year-ago loss, and said on Tuesday it was on track to meet its 2024 outlook, including cutting de
Grifols 2023 Annual Report on Form 20-F filed with the SEC
04:42pm, Friday, 19'th Apr 2024
BARCELONA, Spain , April 19, 2024 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, tod
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
09:30am, Thursday, 18'th Apr 2024
BARCELONA, Spain, April 18, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today officially celeb
LOS ANGELES, CA / ACCESSWIRE / April 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("
LOS ANGELES, CA / ACCESSWIRE / April 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("
Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper
07:16am, Sunday, 14'th Apr 2024
Spanish drug maker Grifols , battling a plunge in its share price this year, plans to add independent directors to its audit and compensation committees to improve its governance, its chairman said in
Grifols to refinance debt due in 2025 via sales of notes, Shanghai RAAS stake
03:43am, Wednesday, 10'th Apr 2024
Spanish drug maker Grifols plans to meet its debt payments in 2025 with the proceeds of new senior secured notes and the sale of its 20% stake in Shanghai RAAS to Haier Group, it said on Wednesday.
LOS ANGELES, CA / ACCESSWIRE / April 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("G
LOS ANGELES, CA / ACCESSWIRE / April 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("G
Spain's Grifols gives new details on past EBITDA, leverage ratios to supervisor
02:22pm, Thursday, 04'th Apr 2024
Spanish drugmaker Grifols on Thursday issued new details of its 2022 and 2023 accounts, including higher leverage ratios than previously reported based on a different calculation of its core earnings
